Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil 2: Spesolimab for prevention of generalized pustular psoriasis flares
jRCT2080225291Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in generalized pustular psoriasis (GPP) comparing spesolimab with placebo (2 arms). Started Jul 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on jRCT2080225291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225291.